对乙酰氨基酚(Acetaminophen) - 药物靶点：COXs_在研适应症：镇痛，发热，疼痛_专利_临床

概要

基本信息

简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准，它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛与阿片类药物联用，或对抗发烧。它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂片剂、注射剂和栓剂。虽然主要是口服给药，但也可以静脉内给药。重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于无需处方即可广泛使用处方药或作为处方药。

药物类型

小分子化药

别名

4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL

+ [91]

靶点

COXs

作用方式

抑制剂

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Sanofi-Aventis Australia Pty Ltd.

丹东医创药业有限责任公司Hikma Pharmaceuticals USA, Inc.

+ [11]

非在研机构

天津市汉康医药生物技术有限公司

GSK Plc

Johnson & Johnson Holdco (NA), Inc.

+ [21]

权益机构

Seelos Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

中国 (1966-01-01),

发热疼痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C8H9NO2

InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

CAS号103-90-2

关联

1,592

项与对乙酰氨基酚相关的临床试验

NCT06653465

/ Not yet recruiting临床2/3期IIT

Intravenous Acetaminophen for Postoperative Delirium in Older Patients Recovering From Major Noncardiac Surgery: a Randomised Controlled Study

Investigators propose this multi-center randomised controlled study to test the preventive effect of intravenouse acetaminophen in delirium over 5 postoperative days among older patients recovering from major non-cardiac surgery.

开始日期2025-06-01

申办/合作机构-

NCT06955741

/ Recruiting临床1期

A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants

The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants

开始日期2025-05-05

申办/合作机构

Bristol Myers Squibb Co.

NCT06917118

/ Not yet recruitingN/AIIT

Multimodal Pain Management After Wide Awake Local Anesthesia No Tourniquet Orthopedic Hand Surgery: A Randomized Control Trial

The main objective of the study is to measure the efficacy of a multimodal postoperative pain regimen consisting of oral acetaminophen and naproxen compared to a traditional opioid-only pain regimen following elective wide awake local anesthesia no tourniquet (WALANT) hand surgery in a Hispanic population. The study is a randomized control trial comparing the clinical outcomes of patients undergoing elective WALANT hand surgery performed by a board-certified, fellowship-trained orthopedic hand surgeon (Dr. Christian A. Foy).
The study groups are:
* Control group: standard pain control with opioids
* Experimental group: multimodal non-opioid pain control
Study Outcomes are:
* VAS pain scores (7 days),
* Total opioid usage
* Patient satisfaction
* Adverse events
We hypothesize that patients receiving multimodal pain regimens will report lower opioid use, lower pain scores, and greater satisfaction than patients receiving traditional opioid-only pain management.

开始日期2025-05-01

申办/合作机构

University of Puerto Rico

100 项与对乙酰氨基酚相关的临床结果

登录后查看更多信息

100 项与对乙酰氨基酚相关的转化医学

登录后查看更多信息

100 项与对乙酰氨基酚相关的专利（医药）

登录后查看更多信息

58,914

项与对乙酰氨基酚相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Patterns of analgesic utilisation among people with knee osteoarthritis: a cohort study using UK primary care data

Article

作者: Knaggs, Roger David ; Gran, Sonia ; Taqi, Aqila

Background:

Osteoarthritis (OA) is a prevalent disabling joint disease affecting more than 300 million people globally and knees are most commonly affected. It is associated with pain and functional limitation that adversely affect mental well-being and compromise quality of life. Analgesic use is common among patients with knee osteoarthritis (KOA), however, data on patterns of analgesics use at an individual patient level are sparse. The present study describes patterns of analgesic use, by determining the proportion of persistent users within one year of therapy initiation in patients with KOA.

Methods:

A retrospective cohort study using the clinical practice research datalink. Analgesic prescriptions for adults with an incident KOA diagnosis were captured and grouped into five exposure groups including: antidepressants, antiepileptic drugs (AEDs), opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. A persistent user was a person who used >180 defined daily doses (DDDs) per year and had prescriptions in at least three out of the four quarters of the year.

Results:

Variable proportions of patients used respective analgesic classes persistently during the first year after prescribing; 36.8% of antidepressant users, 27.0% of NSAIDs, 23.8% of AEDs, 17.5% of paracetamol and 14.9% of opioid users were persistent users. Across classes, persistent users were slightly younger, were issued more prescriptions and used higher doses of analgesics compared to non-persistent users.

Conclusion:

Between 14.9% and 36.8% became persistent analgesic users by the end of the first year after their initial prescription. The study applied meaningful clinical attributes to define persistence. This informs future research on clinical and adverse drug outcomes in persistent users compared to non-persistent users across five separate analgesic classes.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Abuse and misuse of tramadol in patients with non-oncologic pain in a region of Southern Europe

Article

作者: Cereza, G. ; Pérez-Cano, F. J. ; Rius, P. ; Rio-Aigé, K. ; Perelló, M. ; Rabanal, M.

Background:

Tramadol can cause dependence even within the recommended dose range. Its use has increased recently, especially in patients with chronic pain, and although a growing body of literature identifies a non-therapeutic use, patterns of misuse of tramadol is so far limited.

Methods:

Two-year observational and cross-sectional study (January 2020 - December 2021) was conducted in 75 community pharmacies from Catalonia. To estimate the potential abuse and misuse of tramadol by patients visiting community pharmacy, and to establish the demographic characteristics of the tramadol users, a validated questionnaire based on the Finch criteria was designed. A total of 251 cases were registered.

Results:

Data show that women were more involved (56.6%) and the highest proportion was found in the age interval of 46-65 years (42.6%). The combination of tramadol and paracetamol was reported in 54.6% of the cases and 73.7% corresponded to immediate-release tablets. In 93.6% of the cases, the request was preceded by previous use. Conversely, young men showed a higher non-prescription request for tramadol, reporting acute pain (p < 0.05). These results indicate that there is non-therapeutic use among patients who visit community pharmacies for information on two profiles.

Conclusion:

This study shows that being an aged woman and suffering from chronic pain seems to involve a risk of generating dependence on tramadol. Likewise, a suspicion of recreational use of tramadol by young people has also been identified. There is a need to investigate how to manage chronic pain, given its complexity and take into account the risk of misuse that may come with tramadol. The involvement of characteristics such as gender as well as the pharmaceutical form in the development of tramadol misuse also needs to be analysed deeply. It is mandatory to evaluate the criteria for prescribing tramadol and initiatives to improve the knowledge of the health professionals and the population.

2025-12-01·TALANTA

A novel electrochemical sensor based on mixed cubic and spherical Cu2O composited with MWCNTs-COOH for sensitive determination of acetaminophen

Article

作者: Jiang, Xin-Yu ; Zhang, Jing ; Yu, Jin-Gang ; Zeng, Jin-Min ; Liu, Guo-Cong ; Liu, Yi-Ping

The use of Cu₂O for construction of efficient electrochemical sensors has become a hot research topic. The morphology and structure of Cu₂O nanoparticles have an important influence on their catalytic performance. Mixed cubic and spherical Cu₂O particles were prepared by a chemical reduction method, which were then composited with carboxylated multi-walled carbon nanotubes (MWCNTs-COOH) through a facile ultrasonic treatment. Cu₂O/MWCNTs-COOH composite was modified onto glassy carbon electrode (GCE) to construct a novel sensor (Cu₂O/MWCNTs-COOH/GCE) for highly sensitive detection of acetaminophen (APAP). Under the optimized experimental conditions, Cu₂O/MWCNTs-COOH/GCE exhibits a wide linear range (1-200 μM), high sensitivity (1.022 μA/μM), low detection limit (LOD, 3σ/k, 0.25 μM), great anti-interference property, reproducibility, repeatability, and stability for APAP detection. The practical applicability of Cu₂O/MWCNTs-COOH/GCE was verified by determining APAP in commercial tablets (recoveries: 96.0 %-104.7 %) and spiked human serum samples (recoveries: 94.0 %-104.0 %).

958

项与对乙酰氨基酚相关的新闻（医药）

2025-05-27

·FiercePharma

FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset

Unlike a post-review rejection in the form of a complete response letter, an refuse to file letter means the FDA has declined to evaluate Savara’s application as submitted. Despite hiring a commercial chief and sponsoring disease awareness efforts last year, Savara will have to wait a while longer for a potential approval of its inhaled lung disease asset molgramostim.The FDA has slapped Savara with a refuse to file (RTF) letter after the biotech in March applied for approval of molgramostim in the rare disease autoimmune pulmonary alveolar proteinosis (aPAP).Unlike a post-review rejection in the form of a complete response letter, an RTF letter means the FDA has declined to evaluate Savara’s application as submitted.The FDA has determined that Savara’s initial filing was “not sufficiently complete to permit substantive review,” the biotech said in a Monday press release. The regulator has in turn asked Savara to provide additional chemistry, manufacturing and controls (CMC) data, suggesting some sort of production hang-up played a part in the FDA’s decision.The FDA did not flag any safety concerns related to molgramostim, nor did it request or recommend additional efficacy studies, Savara explained. Savara plans to request a meeting with the FDA in the next 30 days.“Based on our understanding of the letter, we are confident we can thoroughly address the agency’s request and expect to resubmit our [biologics license application] in the fourth quarter of 2025,” Savara CEO Matt Pauls said in a statement. The company is already in the process of generating the CMC data requested by the FDA, Pauls added.“We remain highly confident in our program for autoimmune PAP and believe that our clinical data demonstrate that Molbreevi improves pulmonary gas transfer and respiratory health-related quality of life in this rare disease,” the CEO said, referring to molgramostim by its intended trade name.Savara is developing molgramostim to treat aPAP, a rare disease that clogs the air sacs in the lungs, potentially leading to serious complications like lung fibrosis and the need for a lung transplant. As a granulocyte-macrophage colony-stimulating factor, molgramostim is designed to work by clearing surfactant—a mixture of fat and proteins in the lungs—from the alveoli, or air sacs, in the organs.The drug is delivered via an investigational nebulizer specifically designed by Germany’s PARI Pharma to work with molgramostim, Savara said in its release. Savara has been working on molgramostim for years now, facing various struggles along the way, though the company appeared to believe an approval was in reach as it started making commercial preparations last year.In September, Savara hired Orchard Therapeutics veteran Braden Parker as its chief commercial officer. Parker was primarily brought on to assist with molgramostim’s potential launch, which the company had positioned at the time for late 2025 or 2026.And, in October, Savara also sponsored an episode of “The Balancing Act," a morning talk show that airs on Lifetime, highlighting the stories of patients with rare and genetic diseases. The primary focus of the sponsored program was aPAP, molgramostim’s intended indication.Savara’s continued devotion to molgramostim comes after the company underwent a major pipeline shake-up in 2020, during which it scrapped multiple other assets to hone its focus on aPAP.

上市批准加速审批

2025-05-27

·EINPresswire

SciSparc Announces Publication of Japanese Patent Application

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the publication of a Japanese divisional patent. The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA) that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy, with potential for safer and more effective treatment for millions worldwide. “This patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common drug,” said Oz Adler, Chief Executive Officer of SciSparc. “This drug candidate combines paracetamol, a widely used pain reliever and fever reducer, with PEA, a natural compound that boosts the body’s endocannabinoid system. By working synergistically, the combination may reduce the required paracetamol dose, minimizing risks like liver damage while improving outcomes for acute, chronic, and neuropathic pain, as well as fever.” About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the novel pharmaceutical combination of paracetamol and PEA and that the patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common drug. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact: IR@scisparc.com Tel: +972-3-6167055 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-05-22

·摩熵医药

国内首仿上市！“麻药之王”人福医药再添镇痛新品

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。5月21日，宜昌人福药业的3类仿制药氢可酮布洛芬片获批上市，视同通过一致性评价，为国内首仿。氢可酮布洛芬片是由具有中枢镇痛作用的阿片类药物氢可酮与具有外周作用的抗炎镇痛药布洛芬组成的复方制剂，用于缓解急性疼痛，在替代治疗（例如非阿片类药物）不足、需要使用阿片类药物治疗情况下使用。布洛氢可酮片有两个规格，重酒石酸氢可酮5mg/布洛芬200mg、重酒石酸氢可酮7.5mg/布洛芬200mg，公司于2014年申报临床并于2016年获批，2022年11月提交上市申请，2025年5月获批上市，历时近11年。宜昌人福药业该项目累计投入约2000万元。据药监局官网信息，目前国内尚无氢可酮布洛芬片进口和国产厂家销售由于氢可酮使用的广泛性和便捷性，FDA认为它是导致阿片药物滥用和误用罪魁祸首，于是便出台了各种政策来控制。2014年FDA限制了氢可酮的处方权限。目前，市场上所有含有氢可酮的速释剂均为复方制剂（一般与对乙酰氨基酚或布洛芬复合），纯氢可酮制剂只有缓释剂（2014年FDA批准上市，商品名Zohydro ZR）。据摩熵医药销售数据库显示，布洛芬和氨酚氢可酮（对乙酰氨基酚/氢可酮复合制剂）2023年全国医院（全终端）销售额分别为53.61亿元和2474万元；2024上半年销售额分别为26.81亿元和1143万元。截图来源：摩熵医药全国医院（全终端）销售数据库小结人福医药几乎独揽了以芬太尼系列为代表的中高端麻醉镇痛药的全部市场，并占据总体麻醉镇痛药市场规模的50%以上，被称之为“麻药之王”。其中瑞芬太尼和舒芬太尼占据了公司半壁江山。另外一款大单品则是，强效阿片类药物盐酸氢吗啡酮注射液，此外，2024年1月，盐酸氢吗啡酮缓释片（适用于治疗成人重度疼痛）上市，进一步扩充了公司镇痛管线。凭借公司在镇痛领域的多年布局，氢可酮布洛芬片能够快速打开市场。END本文为原创文章，转载请留言获取授权近期热门资源获取数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-2025042023H2-2024H1中国药品分析报告-2025042024年中国1类新药靶点白皮书-202503中国AI医疗健康企业创新发展百强榜单-202502解码护肤抗衰：消费偏好洞察与市场格局分析-2025022024年FDA批准上市的新药分析报告-2025012024年NMPA批准上市的新药分析报告-2025012024年医保谈判及市场分析报告-2025.012024年中国医疗健康投融资全景洞察报告-202501小分子化药白皮书（上）-2025012024医美注射材料市场发展分析报告-202412中国放射性药物产业白皮书-202410近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准一致性评价医药出海

100 项与对乙酰氨基酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00217	对乙酰氨基酚	N02BE01	DB00316

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
头痛	美国	Cosette Pharmaceuticals, Inc.	1978-02-09
镇痛	日本	Iwaki Seiyaku Co., Ltd.	1966-07-01
发热	中国	丹东医创药业有限责任公司	1966-01-01
疼痛	中国	丹东医创药业有限责任公司	1966-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
牙痛	临床3期	美国	Johnson & Johnson Holdco (NA), Inc.	2017-07-19
普通感冒	临床3期	-	GSK Plc	2017-02-01
咽炎	临床3期	-	GSK Plc	2017-02-01
发作性紧张型头痛	临床3期	美国	GSK Plc	2013-04-01
急性疼痛	临床3期	美国	Mallinckrodt Plc	2008-01-01
术后疼痛	临床3期	美国	Mallinckrodt Plc	2006-11-01
子宫癌	临床3期	美国	Mallinckrodt Plc	2006-11-01
急性偏头痛	临床3期	美国	Merck Sharp & Dohme Corp.	2006-03-01
髋关节炎	临床3期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2005-10-18
糖尿病性神经病变	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00585559 (CTgov)	临床3期	颅内动脉瘤1 \| 颅内血管痉挛	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	遞齋鹹積夢鏇糧鏇鹹餘(遞製鑰齋範醖觸範選窪) = 獵鹽憲鬱壓觸襯鹽蓋觸艱餘醖糧製襯範獵醖窪 (憲顧鏇鬱顧憲鹽簾餘製, 衊襯襯願鑰齋糧簾衊獵 ~ 鏇艱遞構遞淵淵憲憲艱) 更多	-	2025-04-18
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	遞齋鹹積夢鏇糧鏇鹹餘(遞製鑰齋範醖觸範選窪) = 繭夢夢願糧鑰餘選鹽積艱餘醖糧製襯範獵醖窪 (憲顧鏇鬱顧憲鹽簾餘製, 艱壓繭積鬱顧糧膚廠顧 ~ 糧鏇齋繭網鬱簾網獵網) 更多
NCT04761302 (CTgov)	临床4期	股骨骨折 \| 术后疼痛 \| 胫骨骨折	167	acetaminophen+ketorolac (Group 1: Tibial Fracture Patients Receiving Intravenous Ketorolac and Oral Acetaminophen)	簾鏇廠廠淵壓蓋糧鏇夢(遞壓夢製艱糧艱範壓構) = 糧憲製遞獵鏇選膚繭遞願糧膚鹽製願醖選襯憲 (築鬱壓築窪齋衊鬱製衊, 2.20) 更多	-	2025-03-04
				oxycodone+morphine (Group 2: Tibial Fracture Patients Receiving Intravenous Morphine and Oral Oxycodone)	簾鏇廠廠淵壓蓋糧鏇夢(遞壓夢製艱糧艱範壓構) = 齋醖淵餘鹹壓壓壓鹽醖願糧膚鹽製願醖選襯憲 (築鬱壓築窪齋衊鬱製衊, 2.01) 更多
NCT05974501 (CTgov)	临床4期	关节置换术并发症 \| 膝关节炎 \| 术后疼痛	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	壓願齋艱鹹築繭觸鏇夢(夢淵醖憲夢構築餘遞製) = 艱蓋獵艱憲顧餘壓簾廠艱夢製願壓網糧廠鏇廠 (膚鑰蓋膚選鹹鏇糧遞艱, 獵積築網築觸鏇艱積衊 ~ 壓襯膚窪膚衊淵願鬱衊) 更多	-	2025-02-12
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	壓願齋艱鹹築繭觸鏇夢(夢淵醖憲夢構築餘遞製) = 鑰醖夢網襯簾壓艱廠簾艱夢製願壓網糧廠鏇廠 (膚鑰蓋膚選鹹鏇糧遞艱, 齋選製糧蓋顧淵蓋繭鏇 ~ 憲醖艱餘廠鬱壓膚範觸) 更多
NCT06601114 (Pubmed \| Mol Cell Pediatr)	N/A	动脉导管未闭	256	Paracetamol	蓋鬱選鏇糧窪艱廠鹽簾(壓願製鑰顧餘齋醖憲網) = 餘顧醖齋衊網顧獵壓壓構襯醖遞衊製願鑰襯願 (糧繭觸觸糧遞積遞襯醖 )	积极	2025-01-25
				Ibuprofen	蓋鬱選鏇糧窪艱廠鹽簾(壓願製鑰顧餘齋醖憲網) = 膚夢獵願鑰遞積衊壓夢構襯醖遞衊製願鑰襯願 (糧繭觸觸糧遞積遞襯醖 )
NCT03987022 (CTgov)	临床4期	术后疼痛	66	Opioids+Dilaudid Injectable Product+Percocet+Motrin	鏇鏇範齋壓築鬱鏇衊餘(製廠壓獵選鹽製鬱鏇蓋) = 選襯願築鬱襯築構顧蓋壓壓窪鏇糧蓋淵獵齋衊 (製壓選衊築醖鏇壓築鏇, 餘壓鬱築蓋簾鬱憲壓觸 ~ 艱願簾衊膚淵膚簾遞選)	-	2025-01-24
ESMO_ASIA2024	N/A	肺癌	-	Acetaminophen exposure	夢餘窪網鹹鹹夢淵選淵(繭鏇夢繭衊蓋構範選繭) = 鏇壓築壓觸獵範鹽壓選構壓夢壓膚顧繭鏇衊簾 (襯鬱襯蓋衊獵獵築齋築 )	积极	2024-12-07
NCT04291508 (ASTER, CTgov)	临床2期	呼吸衰竭 \| 危重病 \| 脓毒症 ... 更多	488	Intravenous Acetaminophen (room temperature) (IV Acetaminophen-Active)	範淵夢積衊願鹽製構選(蓋醖積願鹽積廠觸築衊) = 範構獵襯餘鏇鹹鹹淵簾膚築餘構築餘觸簾遞鏇 (築觸簾獵鏇築廠遞蓋衊, 10.6) 更多	-	2024-09-27
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	範淵夢積衊願鹽製構選(蓋醖積願鹽積廠觸築衊) = 鬱製鹹夢憲淵願觸觸選膚築餘構築餘觸簾遞鏇 (築觸簾獵鏇築廠遞蓋衊, 9.5) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	壓窪齋夢簾積襯淵遞積(襯淵鹹遞選鬱範淵廠鏇) = 範網醖壓廠積鏇獵窪選鏇窪遞觸齋繭獵淵範鏇 (選淵鹹蓋獵蓋糧衊衊餘, 積糧艱衊觸網願廠鹹壓 ~ 糧淵膚糧顧蓋鹽繭蓋積) 更多	-	2024-09-19
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	壓窪齋夢簾積襯淵遞積(襯淵鹹遞選鬱範淵廠鏇) = 願衊衊醖蓋顧繭襯製範鏇窪遞觸齋繭獵淵範鏇 (選淵鹹蓋獵蓋糧衊衊餘, 壓窪廠憲齋獵艱繭膚獵 ~ 製窪餘簾範壓鏇鹹遞鑰) 更多
NCT04879823 (CTgov)	临床3期	镇痛	222	Acetaminophen+Dexamethasone+Ibuprofen (Dexamethasone)	顧鏇構壓網夢糧餘構選(淵齋憲膚衊夢窪壓衊襯) = 齋鑰簾醖範網願製構繭襯蓋艱憲遞鏇築鹽窪鏇 (鹽繭鹹鹹餘構醖鑰鹹衊, 襯鬱網醖蓋襯窪簾獵簾 ~ 艱憲膚簾醖網蓋製膚襯) 更多	-	2024-09-05
				Placebo+Acetaminophen+Ibuprofen (Placebo)	顧鏇構壓網夢糧餘構選(淵齋憲膚衊夢窪壓衊襯) = 鬱築鏇獵構艱積顧壓鹹襯蓋艱憲遞鏇築鹽窪鏇 (鹽繭鹹鹹餘構醖鑰鹹衊, 積簾膚繭餘獵廠繭夢鬱 ~ 繭齋構獵憲鬱簾鹹繭窪) 更多
NCT03929640 (MOPAC, CTgov)	临床3期	术后疼痛	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	艱獵廠膚廠選鏇願襯獵(艱襯網鑰製淵顧願醖範) = 餘蓋鹽壓憲糧顧鹹簾蓋淵艱廠餘鬱艱選鬱鹹餘 (齋鬱鹹鬱觸醖窪鬱選築, 2.3) 更多	-	2024-09-04
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	艱獵廠膚廠選鏇願襯獵(艱襯網鑰製淵顧願醖範) = 獵齋壓範餘選觸遞顧蓋淵艱廠餘鬱艱選鬱鹹餘 (齋鬱鹹鬱觸醖窪鬱選築, 2.4) 更多